These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 864480

  • 1. Plasma DOPA levels and growth hormone response to levodopa in parkinsomism.
    Galea-Debono A, Jenner P, Marsden CD, Parkes JD, Tarsy D, Walters J.
    J Neurol Neurosurg Psychiatry; 1977 Feb; 40(2):162-7. PubMed ID: 864480
    [Abstract] [Full Text] [Related]

  • 2. Plasma DOPA and growth hormone in parkinsonism: oscillations in symptoms.
    Papavasiliou PS, McDowell FH, Wang YY, Rosal V, Miller ST.
    Neurology; 1979 Feb; 29(2):194-200. PubMed ID: 571063
    [Abstract] [Full Text] [Related]

  • 3. [Long-term problems of levodopa therapy in Parkinson disease].
    Albani C, Asper R, Baumgartner G.
    Schweiz Med Wochenschr; 1987 Mar 07; 117(10):347-53. PubMed ID: 3105050
    [Abstract] [Full Text] [Related]

  • 4. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms.
    Bennett JP, Landow ER, Schuh LA.
    Neurology; 1993 Aug 07; 43(8):1551-5. PubMed ID: 8043043
    [Abstract] [Full Text] [Related]

  • 5. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Björklund A, Widner H.
    Brain; 2015 Apr 07; 138(Pt 4):963-73. PubMed ID: 25669730
    [Abstract] [Full Text] [Related]

  • 6. Patterns of clinical response and plasma dopa levels in Parkinson's disease.
    Tolosa ES, Martin WE, Cohen HP, Jacobson RL.
    Neurology; 1975 Feb 07; 25(2):177-83. PubMed ID: 1167646
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
    Muhlack S, Woitalla D, Welnic J, Twiehaus S, Przuntek H, Müller T.
    Neurosci Lett; 2004 Jun 17; 363(3):284-7. PubMed ID: 15182961
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications.
    Sossi V, de la Fuente-Fernández R, Schulzer M, Adams J, Stoessl J.
    Brain; 2006 Apr 17; 129(Pt 4):1050-8. PubMed ID: 16476675
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease.
    Sweet RD, McDowell FH.
    Neurology; 1974 Oct 17; 24(10):953-6. PubMed ID: 4472237
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.